Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pre-Exposure Prophylaxis (PrEP) for HIV Infection

Published byDamon Horn Modified over 5 years ago

Similar presentations

Presentation on theme: "Pre-Exposure Prophylaxis (PrEP) for HIV Infection"— Presentation transcript:

1 Pre-Exposure Prophylaxis (PrEP) for HIV Infection
Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Attending Physician UCLA Center AIDS Research and Education and Ronald Reagan Medical Center Former, Branch Chief, HIV and TB, U.S. CDC South Africa Former, Section Director, STD Prevention and Control Services San Francisco Department of Public Health

2 Disclosures In the past 12 months, I and UCLA Regents have received:
Research funding from Gilead Sciences

3 Outline What is PrEP How well does it work Is it safe
How to offer PrEP Risk reduction counseling Cost and access Resources

4 What is PrEP? Antiretroviral medication to prevent HIV acquisition
Emtricitabine/tenofovir (FTC-TDF) FDA-approved as Truvada, July 2012 One pill, once a day

5 How well does PrEP work to prevent HIV?
Question #1 How well does PrEP work to prevent HIV? 100% effectiveness 65% effectiveness 85% effectiveness It depends

6 How well does PrEP work to prevent HIV?
Question #1 How well does PrEP work to prevent HIV? 100% effectiveness 65% effectiveness 85% effectiveness It depends

7 Effectiveness of PrEP iPrEx FEM-PrEP TDF2 VOICE Partners PrEP PROUD
(TDF/FTC) CI: 15-63 42% FEM-PrEP (TDF/FTC) CI: 6% TDF2 (TDF/FTC) CI: CI: 25-97 49% 80% 99% VOICE (TDF) (TDF/FTC) -49% -4.4% CI: +3 to -129 CI: +27 to -149 Partners PrEP (TDF/FTC) CI: 28-84 CI: 54-94 63% CI: 20-83 CI: 37-87 (TDF) 71% 66% 84% PROUD (TDF/FTC) CI: 58-96 86% iPERGAY (TDF/FTC) CI: 40-99 86% • 7 PrEP pills per week, protection estimated at 99%. • 4 PrEP pills per week, protection estimated at 96%. • 2 PrEP pills per week, protection estimated at 76% In IPrEX study among those with detectable TDF, protection was 92% iPERGAY 2 pills 2-24 hours prior to sex, 1 pill 24 hours after sex, 1 pill 48 hours after sex Slide courtesy of Raphael Landovitz, MD, UCLA

8 What are some common side effects of FTC/TDF (PrEP) to prevent HIV?
Question #2 What are some common side effects of FTC/TDF (PrEP) to prevent HIV? Mild skin rash or fever, occasional vomiting Mild nausea, diarrhea, weight loss Cardiac arrhythmias, liver abnormalities Birth defects, if used in first trimester

9 What are some common side effects of FTC/TDF (PrEP) to prevent HIV?
Question #2 What are some common side effects of FTC/TDF (PrEP) to prevent HIV? Mild skin rash or fever, occasional vomiting Mild nausea, diarrhea, weight loss Cardiac arrhythmias, liver abnormalities Birth defects, if used in first trimester

10 FTC/TDF Side Effects Clinical Sexual health
Mild short-term nausea +/- diarrhea (10%) Decreased appetite + weight loss (5-10%) Reversible small decrease in bone density (1%) Reversible small decrease in kidney function (0.5%) Sexual health Decrease in condom use Increase in syphilis and rectal gonorrhea/ chlamydia • 1 in 10 will have nausea • 1 in 100 will experience decreasing bone mineral density issues • 1 in 200 will have kidney problems

11

12 Case 1 22 year old man, recent syphilis treatment, reports sex with other men Tested HIV-negative 2 months ago What additional history is needed? What tests are needed? Should PrEP be prescribed?

13 When will protection from HIV from
Question #3 When will protection from HIV from PrEP likely occur? After 1 days of use After 3 days of use After 7 days of use After 14 days of use After 28 days of use

14 When will protection from HIV from
Question #3 When will protection from HIV from PrEP likely occur? After 1 days of use After 3 days of use After 7 days of use After 14 days of use After 28 days of use

15 CDC Recommended Indications for PrEP Use by Men who have Sex with Men
Adult man without acute or established HIV infection Any male sex partners in past 6 months Not in a monogamous partnership with a recently tested, HIV-negative man AND at least one of the following Any anal sex without condoms (receptive or insertive) in past 6 months Any STI diagnosed or reported in past 6 months Is in an ongoing sexual relationship with an HIV-infected partner US Public Health Service “Pre-exposure prophylaxis for the prevention of HIV infection in the United States – 2014

16 Case 2 42 year old woman with HIV-infected partner
Partner’s viral load is unknown Has condomless sex when he’s in town Is PrEP indicated? Risks vs. benefits? Baseline history and testing?

17 CDC Recommended Indications for PrEP Use by heterosexually active women
Adult woman without acute or established HIV infection Any sex with opposite sex partner in past 6 months Not in a monogamous partnership with a recently tested HIV-negative partner AND at least one of the following Infrequently uses condoms during sex with 1 or more partners of unknown HIV status who are known to be at substantial risk of HIV infection (IDU or bisexual male partner) Is in an ongoing sexual relationship with an HIV-infected partner US Public Health Service “Pre-exposure prophylaxis for the prevention of HIV infection in the United States – 2014

18 Others at HIV risk Transgender Adults Injection Drug Users
Ask every person their gender identity Ask every person if they have had sex with men, women or both in past 12 months If sexually active with men, ask about types of partnerships, relationships and HIV status of partners Injection Drug Users Any sharing of injection or drug preparation equipment in past 6 months Been in an opiate substitution program in past 6 months Risk of sexual acquisition (also evaluate by MSM and heterosexual criteria)

19 Case 3 36 year old man with fever, chills, mild rash
Reports condomless receptive anal sex 3 weeks ago at a sex club Interested in PrEP

20 Signs and symptoms of acute HIV
Fever Rash Sore throat Headache Swollen glands Diarrhea Source:

21 How common is HIV drug resistance
Question #4 How common is HIV drug resistance among PrEP users? There are at least 100 reported cases Resistance has never happened Rare and usually associated with poor adherence Rare and usually associated with undiagnosed HIV

22 How common is HIV drug resistance
Question #4 How common is HIV drug resistance among PrEP users? There are at least 100 reported cases Resistance has never happened Rare and usually associated with poor adherence Rare and usually associated with undiagnosed HIV

23 FTC/TDF for PrEP and Resistance
7 with resistance: 5 of 7 with HIV before starting FTC/TDF No resistance developed in treatment arm Adapted from PrEP in the Real World

24 Typical Clinical Evaluation
Baseline HIV testing 4th gen HIV Ab/Ag* STI screening for syphilis, rectal chlamydia/ gonorrhea and pharyngeal gonorrhea Hepatitis B & C screening HBV vaccine if non-immune Kidney function testing Every 3 month follow-up HIV testing 4th gen HIV Ab/Ag STI screening for syphilis, rectal chlamydia/ gonorrhea and pharyngeal gonorrhea Kidney function testing (3 months then 6-monthly) Bone scan not recommended Pregnancy test for women who may become pregnant *Any suspicion acute HIV = HIV RNA testing

25 Prescribe PrEP FTC/TDF 1 tab daily by mouth, #30, refills x 2
Follow-up visit at 1 month to review dosing, adherence, side-effects Manage other interventions, vaccinations, etc. Risk-reduction counseling How do you keep yourself at low risk from STIs? Any substance use issues? How does substance use impact sexual behavior? Strong recommendation for condom use Identify at least one concrete step to reduce risk

26 Possible Concrete Risk Reduction Steps
Carry condoms before going out Ask partner about condom use Reduce alcohol use when seeking sex Ask partner about recent HIV/STD testing Limit number of new sex partners of unknown status/ testing history

27 Clinical setting and team
Routine primary care Create PrEP friendly setting Use CDC infographics PrEP champion Add tools into e-health system Best practice advisories Patient self-completed risk assessment Social worker or benefits expert

28 Average Wholesale Price
$1800 for 30-day supply FTC/TDF Average annual cost of HIV care =$23,000* *Gebo KA et al, AIDS 2010

29 Medication Assistance
Gilead will provide FTC/TDF for PrEP at no cost for individuals who qualify for the assistance program (< 500% poverty level) Gilead will provide Co-Pay assistance for insured patients Program Element PrEP Medication Assistance Program Eligibility Criteria US resident, uninsured or no drug coverage, HIV-negative, low income Drug Fulfillment Product dispensed by Covance Specialty Pharmacy, labeled for individual patient use and shipped to prescriber (30 day supply); no card or voucher option Recertification Period 6 months, with 90 day status check Main Message For those who are uninsured, the PA Program may be able to help. Truvada will be delivered to the HCP office. The PAP reinforces the REMS program .

30 Online Resources orderprepbooklets/

31 Conclusions on PrEP PrEP works PrEP is safe
PrEP may be prescribed by primary care and mid-level providers PrEP use is associated with increased risk behavior and increased number of STDs, … regular screening and risk reduction counseling are critical

32 Thank you QUESTIONS?

Download ppt "Pre-Exposure Prophylaxis (PrEP) for HIV Infection"

Similar presentations

Recommendations for STD Clinical Preventive Services for Persons Living with HIV/AIDS.

Recommendations for STD Clinical Preventive Services for Persons Living with HIV/AIDS.
Perspectives on Outreach from the NYC Department of Health and Mental Hygiene Benjamin Tsoi, MD, MPH Bureau of HIV/AIDS Prevention and Control NYC Department.

Perspectives on Outreach from the NYC Department of Health and Mental Hygiene Benjamin Tsoi, MD, MPH Bureau of HIV/AIDS Prevention and Control NYC Department.
Self and Partner Examination for Syphilis Symptoms among MSM Brandy Peterson, MPH, CHES Melanie Taylor, MD, MPH ADHS/STDP Statewide STD Meeting September.

Self and Partner Examination for Syphilis Symptoms among MSM Brandy Peterson, MPH, CHES Melanie Taylor, MD, MPH ADHS/STDP Statewide STD Meeting September.
PrEP: HIV Pre-exposure Prophylaxis Katherine Marx, MS, MPH, FNP-BC June 2014.

PrEP: HIV Pre-exposure Prophylaxis Katherine Marx, MS, MPH, FNP-BC June 2014.
Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.

Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.
--IMPORTANT UPDATE FOR 2014-- Increased Syphilis and HIV among Men Who Have Sex with Men 1 Alaska is experiencing a spike in the number of reported cases.

--IMPORTANT UPDATE FOR Increased Syphilis and HIV among Men Who Have Sex with Men 1 Alaska is experiencing a spike in the number of reported cases.
Hepatitis B and Hepatitis B Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.

Hepatitis B and Hepatitis B Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention

Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Incorporating HIV Prevention into the Medical Care of Persons Living with HIV Ask ∙ Screen ∙ Intervene Developed by: The National Network of STD/HIV Prevention.

Incorporating HIV Prevention into the Medical Care of Persons Living with HIV Ask ∙ Screen ∙ Intervene Developed by: The National Network of STD/HIV Prevention.
New York State Department of Health AIDS Institute June, 2014

New York State Department of Health AIDS Institute June, 2014
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
STD Testing Protocols, STD Testing, and Discussion of Sexual Behaviors in HIV Clinics in Los Angeles County Melanie M. Taylor MD, MPH Los Angeles County.

STD Testing Protocols, STD Testing, and Discussion of Sexual Behaviors in HIV Clinics in Los Angeles County Melanie M. Taylor MD, MPH Los Angeles County.
African Americans and HIV: CA Office of AIDS Response Michelle Roland, MD Chief, Office of AIDS California Department of Public Health.

African Americans and HIV: CA Office of AIDS Response Michelle Roland, MD Chief, Office of AIDS California Department of Public Health.
N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER PrEP 201: Beyond the Basics Joanne Stekler, MD MPH Associate Professor of Medicine University of Washington.

N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER PrEP 201: Beyond the Basics Joanne Stekler, MD MPH Associate Professor of Medicine University of Washington.
Antiretroviral Postexposure Prophylaxis after Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV in the United States Recommendations.

Antiretroviral Postexposure Prophylaxis after Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV in the United States Recommendations.
Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.

Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.
SSuN: MSM prevalence monitoring and HIV Testing in STD Clinics Kristen Mahle & Lori Newman SSuN Call #3 Oct 30, 2008.

SSuN: MSM prevalence monitoring and HIV Testing in STD Clinics Kristen Mahle & Lori Newman SSuN Call #3 Oct 30, 2008.
Introduction to NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Office of the Director Jonathan Mermin, MD, MPH National.

Introduction to NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Office of the Director Jonathan Mermin, MD, MPH National.
ART: When to Start? – Case Discussion Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell.

ART: When to Start? – Case Discussion Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell.

Similar presentations

Ads by Google